Dental Implants with Osteoporosis: Can You Still Get Them in the UK?

If you have been diagnosed with osteoporosis and a UK clinic has hinted that implants might be off the table, the picture is more nuanced than a flat yes or no. Osteoporosis on its own does not bar you from dental implants, but the medication used to treat it can change the risk profile, and good UK clinics will plan around that rather than refuse outright. This guide sets out what the evidence and current UK guidance actually say in 2026.

TL;DR

Osteoporosis is not an automatic block to dental implants in the UK. Multiple peer-reviewed studies show implant survival in osteoporotic patients is broadly comparable to the general population when planning, surgery and aftercare are adjusted for bone quality. The bigger flag is the medication. Oral bisphosphonates taken for osteoporosis carry a small but real risk of medication-related osteonecrosis of the jaw (MRONJ), with high-risk intravenous antiresorptives raising that risk further. UK guidance from SDCEP and the Royal Osteoporosis Society treats most oral bisphosphonate users as low risk for routine implant surgery, while flagging high-risk groups for specialist assessment. Expect a thorough medical history, CBCT planning, a frank conversation about MRONJ, and possibly a slower healing protocol rather than an outright refusal.

Why osteoporosis matters for implants

Osteoporosis is a systemic condition in which bone density and microarchitecture decline, raising the risk of fractures at the hip, spine and wrist. The jawbones are not the worst affected sites, but they are not immune. For implant surgery the question is twofold: does the jaw still have the volume and quality of bone needed to hold a fixture, and does the body have the biology to integrate it once placed.

UK epidemiological work indexed on PubMed consistently shows that postmenopausal women are the largest patient group with osteoporosis, although men and younger people with risk factors can also be affected. The Royal Osteoporosis Society puts the UK prevalence at around three million people, which means implant teams see osteoporotic patients every week. Our companion piece on hormones, bone and implants in women over 50 covers the wider hormonal picture; this article focuses specifically on the osteoporosis diagnosis itself.

What the evidence says about implant success

The widely held fear is that an osteoporotic jaw cannot grip an implant well enough to integrate. The data softens that fear considerably. Systematic reviews comparing implant survival in osteoporotic and non-osteoporotic patients consistently show similar long-term survival rates, often within a few percentage points of each other. Where differences appear, they tend to be in early healing markers such as marginal bone level changes, rather than in catastrophic failure.

That is not the same as saying osteoporosis is irrelevant. Lower bone density can mean a softer drilling feel during surgery and a slower path to full osseointegration, the biological process by which the implant fuses with bone. Surgeons adjust for this with technique choices: undersized drilling to preserve bone, slightly longer or wider fixtures to spread load, and longer healing windows before the crown goes on. Our piece on implant failure rates puts these tweaks in the wider context of why implants fail when they do.

Bisphosphonates and the MRONJ question

The bigger clinical question is rarely the disease itself. It is the medication. Bisphosphonates such as alendronate, risedronate and ibandronate are first-line oral treatments for osteoporosis in the UK, prescribed in line with NICE guidance. They work by slowing the bone-resorbing cells that constantly remodel the skeleton. That slowing is precisely what protects against fragility fractures, but it also alters how the jaw heals after surgery.

The complication everyone talks about is medication-related osteonecrosis of the jaw, or MRONJ. In MRONJ, exposed bone in the jaw fails to heal after a dental procedure and can become chronically infected. It is rare. UK and international estimates put the risk after dental extractions or implant surgery at well under 1 percent in patients on oral bisphosphonates for osteoporosis, rising substantially in patients on intravenous bisphosphonates or denosumab for cancer-related bone disease.

The Scottish Dental Clinical Effectiveness Programme SDCEP guidance on managing the dental patient on antiresorptive medication splits patients into low and higher risk categories. Most osteoporosis patients on oral bisphosphonates for less than five years, with no other risk factors, are treated as low risk and can usually proceed with implant surgery from a general implant practice with appropriate consent. Patients on long-term oral therapy, intravenous antiresorptives, or with concurrent risk factors such as steroid use or diabetes are pushed up the risk ladder and often referred for specialist assessment.

Other osteoporosis medications

Bisphosphonates are not the only antiresorptive in UK use. Denosumab, marketed as Prolia for osteoporosis, is a twice-yearly injection that suppresses bone remodelling by a different mechanism. It also carries an MRONJ risk, and importantly that risk falls more quickly after stopping the drug than with bisphosphonates, because denosumab does not bind to bone long term.

Anabolic agents such as teriparatide, used for severe osteoporosis, stimulate bone formation rather than suppress resorption. They have not been linked to MRONJ in the same way and in some clinical contexts may even be protective for healing.

Hormone replacement therapy, raloxifene and other selective oestrogen receptor modulators are also part of the UK osteoporosis toolkit. None carries the MRONJ signal seen with antiresorptives. Patients on these treatments are usually assessed like any other implant candidate, with attention to bone quality but no special MRONJ protocol.

How UK clinics assess risk before treatment

A responsible UK implant consultation for an osteoporotic patient looks different from a standard one. Expect a detailed medical history that asks not just whether you take osteoporosis medication, but which one, for how long, at what dose, and whether any intravenous treatment has ever been given for any reason. A patient who had IV zoledronate years ago for cancer-related care is in a very different risk band from someone who started oral alendronate last year.

A CBCT scan is non-negotiable. It maps the three-dimensional bone available, shows density patterns and confirms whether a graft might be needed. Our CBCT cost guide covers what to expect from this scan in 2026, and a clinic quoting implants for an osteoporotic patient without one is cutting corners.

The clinic should also coordinate with your GP or, where relevant, the rheumatology or endocrinology team prescribing the antiresorptive. There is no UK consensus that bisphosphonates need to be stopped before routine dental implant surgery in low-risk osteoporosis patients, and decisions to interrupt therapy ("drug holidays") should never be taken by the dentist alone, because of the fracture risk that suspending treatment carries.

Tailoring the surgery and healing window

Several practical adjustments make implant surgery in an osteoporotic patient safer. Atraumatic technique matters more than usual: the surgeon aims to minimise heat and mechanical insult to bone that has less spare capacity to remodel. Primary closure of the gum over the surgical site is preferred where possible, because exposed bone is the entry point for MRONJ.

Antibiotic cover is often used around the surgery in higher-risk cases, in line with SDCEP and clinic-specific protocols. Antiseptic mouthwashes such as chlorhexidine help keep the site clean during the early healing window.

Healing timelines tend to be extended. Where a standard implant might be restored at three to four months in a healthy patient, an osteoporotic patient on antiresorptive medication may be asked to wait four to six months, or even longer in higher-risk cases, before the crown is loaded. This patience is one of the main reasons survival rates can match the general population: the biology gets the time it needs. Our implant recovery guide covers the first month in detail, most of which applies, with stretched timelines further out.

When implants are not the right call

There are still scenarios where most UK implant teams will pause or decline. Patients currently on high-dose intravenous antiresorptives for cancer-related bone disease are typically advised against elective implants because the MRONJ risk is meaningfully higher. Patients with a previous episode of MRONJ at any site are usually excluded from further elective implant surgery, since the predictor is so strong. Severe uncontrolled osteoporosis combined with other systemic risks, such as long-term steroid therapy or smoking, may push the cumulative risk above what an elective procedure can justify.

For some of these patients, alternatives are worth discussing. A well-fitted denture, an adhesive bridge, or in selected cases an implant-supported overdenture with fewer fixtures may give an acceptable outcome with less surgical insult to the jaw. The point of a good consultation is to find the right answer for your circumstances rather than a flat refusal.

NHS, private and cost expectations

For the vast majority of UK osteoporosis patients, implants remain private treatment. The NHS provides implants only in a tightly defined set of medical and reconstructive cases, summarised in our guide on who qualifies for NHS implants. Standard tooth replacement for an osteoporotic patient does not usually meet that bar.

Private costs in 2026 are broadly in line with implants for any other patient: roughly £2,200 to £3,500 per single implant including the crown, with additional fees for any bone augmentation. Where osteoporosis can push the bill up is in the planning side. Expect a more thorough consultation, possibly a specialist referral, and the CBCT scan as a non-optional line item. If you have been told you need bone grafting on top, that is a separate cost again. Always ask for these items individually on a written quote rather than buried in a bundled fee, and compare what is and is not included between clinics.

Who should do the work

Choice of clinician matters more than usual. Low-risk osteoporosis cases on oral bisphosphonates can sit comfortably within the scope of an experienced general implant dentist who follows SDCEP guidance, knows when to refer, and works to the clinical standards published by the Royal College of Surgeons of England. Higher-risk cases, or anything involving complex grafting in an antiresorptive-treated patient, lean toward specialist oral surgeons or specialist implantologists.

You can confirm any clinician's GDC registration and any specialist listing on the General Dental Council register. The British Dental Association is a useful background reference on UK professional standards, and the Care Quality Commission regulates practices in England, with equivalent regulators in Scotland, Wales and Northern Ireland. The wider context for older patients is covered in our piece on dental implants after 60, much of which overlaps with the osteoporosis demographic.

FAQ

Can I have dental implants if I have osteoporosis?

In most cases yes. UK clinical experience and peer-reviewed data show implant survival in osteoporotic patients is comparable to the general population when planning is done well. The conversation centres on which osteoporosis medication you take, for how long, and any other risk factors, rather than the diagnosis on its own. A thorough consultation with a CBCT scan and, where needed, liaison with your GP or specialist sets the path.

Do I need to stop my bisphosphonates before implant surgery?

Usually not, if you are on oral bisphosphonates for osteoporosis and otherwise low risk. UK guidance does not routinely recommend stopping these drugs ("drug holidays") for elective dental surgery, because stopping carries its own fracture risk. Any decision to interrupt antiresorptive treatment should involve your prescribing doctor, never the dentist alone. Higher-risk situations, including patients on intravenous antiresorptives, are handled case by case in specialist settings.

What is MRONJ and how likely is it?

MRONJ stands for medication-related osteonecrosis of the jaw. It is a rare condition in which exposed bone in the jaw fails to heal after a dental procedure. For patients on oral bisphosphonates for osteoporosis, the risk after implant surgery is widely reported as well under 1 percent in published reviews. Risk rises with intravenous antiresorptive therapy, denosumab use, long treatment duration, steroid use, smoking and diabetes. Good surgical technique and aftercare reduce the risk further.

Will my implants fail faster because of osteoporosis?

Long-term implant survival in osteoporotic patients is broadly similar to non-osteoporotic patients in most published series, often within a couple of percentage points. Some studies report slightly greater early marginal bone loss, which clinics manage with adjusted drilling protocols and longer healing windows before loading the crown. Patient factors such as smoking, diabetes and oral hygiene weigh more heavily on long-term outcomes than the osteoporosis diagnosis itself.

Does the NHS pay for dental implants for osteoporosis patients?

In nearly all cases, no. NHS dental implants are limited to a narrow set of medical and reconstructive indications, and standard tooth replacement for an osteoporosis patient does not usually qualify. The condition is not, on its own, a route into NHS-funded implant care. Most patients are seen privately, with prices in 2026 broadly similar to other private implant patients plus the cost of any extra planning and grafting.

Should I see a specialist rather than a general dentist?

Not automatically. Low-risk osteoporosis cases on oral bisphosphonates can be treated by experienced general implant dentists who follow SDCEP guidance. Specialist referral is more important if you are on intravenous antiresorptives, denosumab, long-duration therapy, have other risk factors such as steroid use, or need complex bone augmentation. A reputable general clinic will recognise when to refer and say so, rather than press ahead with a case beyond its comfort zone.